The Food and Drug Administration approved the deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) as an adjunctive therapy for drug-resistant epilepsy (DRE) in the United States in 2018. The DBS Therapy for Epilepsy Post-Approval Study is further evaluating the safety and effectiveness of ANT-DBS among different patients’ groups. For this study, devices for vagus nerve stimulation (VNS) must be removed prior to enrolment.

中文翻译：

---

丘脑深部脑前核刺激伴随迷走神经刺激治疗耐药性癫痫

2018 年，美国食品药品监督管理局批准丘脑前核深部脑刺激（ANT-DBS）作为耐药性癫痫（DRE）的辅助治疗。DBS 治疗癫痫批准后研究正在进一步评估不同患者组中 ANT-DBS 的安全性和有效性。对于这项研究，迷走神经刺激 (VNS) 设备必须在入组前移除。